ITTO20110641A1 - Composizioni farmaceutiche e metodi di trattamento - Google Patents

Composizioni farmaceutiche e metodi di trattamento

Info

Publication number
ITTO20110641A1
ITTO20110641A1 IT000641A ITTO20110641A ITTO20110641A1 IT TO20110641 A1 ITTO20110641 A1 IT TO20110641A1 IT 000641 A IT000641 A IT 000641A IT TO20110641 A ITTO20110641 A IT TO20110641A IT TO20110641 A1 ITTO20110641 A1 IT TO20110641A1
Authority
IT
Italy
Prior art keywords
pharmaceutical compositions
treatment methods
treatment
methods
pharmaceutical
Prior art date
Application number
IT000641A
Other languages
English (en)
Inventor
Liudmila Fyodorovna Dolgovyh
Julia Leonidovna Dugina
Oleg Iliich Epshtein
Irina Anatolievna Kheyfets
Svetlana Alexandrovna Sergeeva
Sergey Alexandrovich Tarasov
Julia Alexandrovna Zabolotneva
Original Assignee
Oleg Iliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ITTO20110641(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010129289/15A external-priority patent/RU2552221C2/ru
Priority claimed from RU2010130350/15A external-priority patent/RU2533224C2/ru
Priority claimed from RU2011122407A external-priority patent/RU2610438C2/ru
Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein
Publication of ITTO20110641A1 publication Critical patent/ITTO20110641A1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT000641A 2010-07-15 2011-07-15 Composizioni farmaceutiche e metodi di trattamento ITTO20110641A1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2010129289/15A RU2552221C2 (ru) 2010-07-15 2010-07-15 Способ лечения ожирения и сопутствующих метаболических расстройств и лекарственное средство для лечения ожирения и сопутствующих метаболических расстройств
RU2010130350/15A RU2533224C2 (ru) 2010-07-21 2010-07-21 Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
RU2011122407A RU2610438C2 (ru) 2011-06-02 2011-06-02 Способ лечения патологического синдрома и лекарственное средство центрального и периферического действия для лечения патологического синдрома

Publications (1)

Publication Number Publication Date
ITTO20110641A1 true ITTO20110641A1 (it) 2012-01-16

Family

ID=44899164

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000641A ITTO20110641A1 (it) 2010-07-15 2011-07-15 Composizioni farmaceutiche e metodi di trattamento

Country Status (30)

Country Link
US (1) US8865163B2 (it)
EP (1) EP2593477A2 (it)
JP (1) JP2013535436A (it)
KR (1) KR20140012009A (it)
CN (1) CN103124742A (it)
AR (1) AR082246A1 (it)
AU (1) AU2011278040B2 (it)
BR (1) BR112013000841A2 (it)
CA (1) CA2805091A1 (it)
CL (1) CL2013000098A1 (it)
CZ (1) CZ2013104A3 (it)
DE (1) DE112011102349T5 (it)
DK (1) DK201370078A (it)
EA (1) EA029400B1 (it)
EE (1) EE05760B1 (it)
ES (1) ES2542042R1 (it)
FI (1) FI20135146A7 (it)
FR (1) FR2962653A1 (it)
GB (1) GB2496076B (it)
IT (1) ITTO20110641A1 (it)
LT (1) LT5987B (it)
MX (1) MX361778B (it)
MY (1) MY158183A (it)
NO (1) NO20130219A1 (it)
NZ (1) NZ606768A (it)
PE (1) PE20131338A1 (it)
PH (1) PH12013500109A1 (it)
SE (1) SE1350179A1 (it)
SG (1) SG187037A1 (it)
WO (1) WO2012007847A2 (it)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
WO2012017324A2 (en) 2010-07-15 2012-02-09 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
SG10201505561TA (en) 2010-07-15 2015-08-28 Oleg Iliich Epshtein A Method Of Increasing The Effect Of An Activated-Potentiated Form Of An Antibody
SG187036A1 (en) * 2010-07-15 2013-02-28 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating genitourinary system disorders
SG187578A1 (en) * 2010-07-21 2013-03-28 Oleg Iliich Epshtein A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
AU2011281244A1 (en) 2010-07-21 2013-03-07 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
AU2011281247B2 (en) * 2010-07-21 2015-07-30 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
US20130058981A1 (en) * 2010-07-21 2013-03-07 Oleg Iliich Epshtein Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
ES2510940R1 (es) * 2010-08-06 2015-03-27 Oleg Iliich Epshtein Composición farmacéutica combinada y su uso para preparar un medicamento destinado al tratamiento y prevención de las enfermedades infecciosas
RU2013111962A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
MX2016012403A (es) 2014-03-27 2017-06-14 Bird Rock Bio Inc Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano.
CN104524568B (zh) * 2015-01-08 2018-04-20 中国人民解放军第二军医大学 一种治疗肥胖症的药物组合物及其应用
EP3356833A4 (en) 2015-09-30 2019-04-10 Bird Rock Bio, Inc. ANTIBODIES FOR BINDING HUMAN CANNABINOID RECEPTOR 1 (CB1)
EP4021505B1 (en) * 2019-08-29 2023-12-13 Oleg Iliich Epshtein Medicament for treating infectious diseases

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
AU723812B2 (en) 1996-02-12 2000-09-07 Oleg Iliich Epshtein Medicinal preparation and a method of medicinal action on human organism
US5849528A (en) 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
RU2156621C1 (ru) 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2209084C1 (ru) * 2001-12-26 2003-07-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения депрессивных расстройств
RU2201255C1 (ru) 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76640C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб
UA76639C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
CN101107003B (zh) 2003-03-14 2012-08-08 营养学研究有限公司 用于治疗疼痛和/或炎症的顺势疗法的配剂
US20050100513A1 (en) * 2003-11-10 2005-05-12 Watkins Mary B. Homeopathic method and system for treating nicotine addiction
EP1574211A1 (en) * 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
RU2437678C2 (ru) 2006-06-06 2011-12-27 Олег Ильич Эпштейн Лекарственное средство для перорального лечения ожирения и способ получения твердой лекарственной формы для пероральной терапии ожирения
RU2438707C2 (ru) * 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
KR20090024241A (ko) * 2006-06-06 2009-03-06 올레그 일리치 엡쉬테인 비만, 당뇨병 및 내당능 장애 관련 질병 치료용 약제
CL2007003002A1 (es) * 2006-10-23 2008-06-06 Eli Lilly And Company Soc Oran Compuesto 3-[1-metil-1-(6-trifluorometil-piridin-3-il)-etilamino]-5-(3-trifluorometoxifenil)-1-(4-trifluorometil-fenil)-pirrolidin-2-ona; y uso para el tratamiento de un trastorno seleccionado de obesidad, esquizofrenia, abuso de sustancias o depende
EP1985295A1 (en) 2007-04-04 2008-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
JP2010132631A (ja) * 2008-11-04 2010-06-17 Bizen Chemical Co Ltd カンナビノイド受容体のインバースアゴニストおよびアンタゴニスト活性を有する組成物
WO2012017324A2 (en) 2010-07-15 2012-02-09 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
PE20130397A1 (es) 2010-07-15 2013-04-10 Oleg Iliich Epshtein Composicion farmaceutica combinada y metodos para el tratamiento de las enfermedades o condiciones funcionales del tracto gastrointestinal
SG187578A1 (en) 2010-07-21 2013-03-28 Oleg Iliich Epshtein A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
AU2011281244A1 (en) 2010-07-21 2013-03-07 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
MX2013000808A (es) 2010-07-21 2013-10-28 Oleg Iliich Epshtein Un metodo para el tratamiento de la enfermedad de alzheimer.
FR2962914A1 (fr) 2010-07-21 2012-01-27 Oleg Iliich Epshtein Composition pharmaceutique destinee a etre utilisee dans un procede pour traiter les maladies organiques du systeme nerveux, le syndrome psycho-organique et l'encephalopathie
US20130058981A1 (en) 2010-07-21 2013-03-07 Oleg Iliich Epshtein Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia

Also Published As

Publication number Publication date
MY158183A (en) 2016-09-15
CL2013000098A1 (es) 2015-01-16
JP2013535436A (ja) 2013-09-12
PE20131338A1 (es) 2013-11-18
FR2962653A1 (fr) 2012-01-20
SE1350179A1 (sv) 2013-04-12
NZ606768A (en) 2015-08-28
CZ2013104A3 (cs) 2013-05-29
DE112011102349T5 (de) 2013-04-18
BR112013000841A2 (pt) 2016-06-07
ES2542042R1 (es) 2015-10-06
WO2012007847A3 (en) 2012-04-12
CN103124742A (zh) 2013-05-29
ES2542042A2 (es) 2015-07-29
EE201300005A (et) 2013-08-15
AU2011278040A1 (en) 2013-03-07
EP2593477A2 (en) 2013-05-22
GB2496076A (en) 2013-05-01
US20130017202A1 (en) 2013-01-17
AR082246A1 (es) 2012-11-21
PH12013500109A1 (en) 2015-07-03
EA029400B1 (ru) 2018-03-30
AU2011278040B2 (en) 2016-06-02
WO2012007847A2 (en) 2012-01-19
US8865163B2 (en) 2014-10-21
LT2013015A (lt) 2013-11-25
NO20130219A1 (no) 2013-03-22
LT5987B (lt) 2014-01-27
KR20140012009A (ko) 2014-01-29
SG187037A1 (en) 2013-02-28
GB201302653D0 (en) 2013-04-03
MX361778B (es) 2018-12-17
CA2805091A1 (en) 2012-01-19
DK201370078A (en) 2013-02-14
GB2496076B (en) 2018-05-09
EA201300133A1 (ru) 2014-03-31
EE05760B1 (et) 2016-03-15
FI20135146L (fi) 2013-02-15
MX2013000545A (es) 2013-10-28
FI20135146A7 (fi) 2013-02-15

Similar Documents

Publication Publication Date Title
ITTO20110641A1 (it) Composizioni farmaceutiche e metodi di trattamento
SMT201600350B (it) Composizioni farmaceutiche
SMT201700008B (it) Composizione farmaceutica
DK3246018T3 (da) Farmaceutisk sammensætning
BRPI1011587A2 (pt) compostos e composições terapèuticas
DK3284467T3 (da) Nikotinholdige farmaceutiske sammensætninger
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
BR112013014644A2 (pt) composição farmacêutica e complexo
IL232262A (en) Therapeutic agents and uses thereof
GT201200303A (es) Formulaciones farmacéuticas
EP2804599A4 (en) PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS
BR112012000831A2 (pt) compostos, composições farmacêuticas e métodos relacionados
PL2718434T3 (pl) Kompozycje i sposoby leczenia choroby trzewnej
CO6801722A2 (es) Composiciones farmacéuticas
ZA201402820B (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
DK3156060T3 (da) Farmaceutiske sammensætninger og topisk anvendelse deraf
BR112013008074A2 (pt) combinações farmacêuticas
SMT201500005B (it) Composizione framaceutica inalabile
BR112013014915A2 (pt) composição curativa e métodos de tratamento
BR112013003275A2 (pt) composição de tratamento oral
BR112015002646A2 (pt) composto e composição farmacêutica
EP2635307A4 (en) PHARMACEUTICAL COMPOSITIONS
BR112012029461A2 (pt) composição farmacêutica contendo solifenacina
BR112012029669A2 (pt) composição e método
BR112013022530A2 (pt) método terapêutico homeopático e composições